A8171-10mg | Entinostat (MS-275,SNDX-275) [209783-80-2] Clinisciences

Background

Entinostat (also known as MS-275 or SNDX-275), a derivative of 2-aminophenyl benzamides, is a potent and orally-available inhibitor of histone deacetylases (HDACs), a family of enzymes associated with a variety of well-characterized cellular oncogenes and tumor suppressors, that potently inhibits class I HDACs, including HDAC1, HDAC3 and HDAC8, with values of 50% inhibition concentration IC₅₀ of 0.368 μM, 0.501 μM and 63.4 μM respectively. Entinostat has been widely investigated for the treatment of cancer, in which results have shown the in vitro anti-proliferative activity of entinostat in a wide range of human cancer cell lines, including breast, colon, lung, myeloma, ovary, pancreas, prostate and leukemia.

Reference

Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. Int J Biochem Cell Biol. 2007;39(7-8):1388-405. Epub 2007 Feb 16.

Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol. 2005 Mar;84(2-3):109-21.

Product Citation

1. Aran Merati, Spandana Kotian, et al. "Glioma Stem Cells Are Sensitized to BCL-2 Family Inhibition by Compromising Histone Deacetylases." Int J Mol Sci. 2023 Sep 5;24(18):13688. PMID: 37761989
2. AKANSHA M. SHAH, LEI GUO, et al. "TWIST2-mediated chromatin remodeling promotes fusion-negative rhabdomyosarcoma." SCIENCE ADVANCES. 28 Apr 2023 Vol 9, Issue 17.
3. Manna PR, Ramachandran S, et al. "Expression and Function of StAR in Cancerous and Non-Cancerous Human and Mouse Breast Tissues: New Insights into Diagnosis and Treatment of Hormone-Sensitive Breast Cancer." Int J Mol Sci 2023 Jan 01;24(1) PMID: 36614200
4. Schwartz, Hannah, et al. "In vitro Methods to Better Evaluate Drug Responses in Cancer." UMass Chan Medical School. September 8, 2022.
5. Wang MH, Wu CH, et al. "Nerve-mediated expression of histone deacetylases regulates limb regeneration in axolotls." Dev Biol. 2019 May 15;449(2):122-131. PMID: 30826398
6. Manna PR, Ahmed AU, et al. "Overexpression of the steroidogenic acute regulatory protein in breast cancer: Regulation by histone deacetylase inhibition." Biochem Biophys Res Commun. 2019 Feb 5;509(2):476-482. PMID: 30595381
7. Bagnall NH, Hines BM, et al. "Insecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, Lucilia cuprina." Int J Parasitol Drugs Drug Resist. 2017 Apr;7(1):51-60. PMID: 28110187

Hide ↑↑

Chemical Properties

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	376.4
Cas No.	209783-80-2
Formula	C₂₁H₂₀N₄O₃
Synonyms	MS-275,SNDX-275, MS 275, MS-27-275, SNDX275, Histone Deacetylase Inhibitor I, MS27-275
Solubility	insoluble in H2O; ≥18.8 mg/mL in DMSO; ≥7.4 mg/mL in EtOH with ultrasonic
Chemical Name	pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate
SDF	Download SDF
Canonical SMILES	C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3
Shipping Condition	Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips	We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment:[1]
Cell lines	Y79, Weri-Rb1, and Y79-LUC human RB cell lines, and Rb143 primary human RB cells
Preparation method	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
Reaction Conditions	Dependent on situations
Applications	TSA, SAHA, and MS-275 dose dependently reduced RB cell survival. TSA and MS-275 showed additive growth-inhibitory effects in combination with carboplatin, etoposide, or vincristine. TSA and MS-275 increased caspase-3/7 activity. MS-275 increased Annexin V membrane translocation and induced G1arrest. Cytotoxicity of MS-275 was dependent on increased reactive oxygen species levels and was reversed by antioxidant pretreatment.
Animal experiment:[1]
Animal models	LHh-Tag transgenic murine model and a rat Y79-LUC ocular xenograft model
Dosage form	LHh-Tag mice were treated every other day for 21 d with 20 mg/kg MS-275; Y79-LUC ocular xenografts mice were treated every other day for 13 d with 20 mg/kg MS-275.
Applications	Intraocular administration of 1μl of 10 μM MS-275 did not alter ocular tissue morphology. Increased acetyl-histone levels confirmed MS-275 delivery to retinal tissue after systemic administration. MS-275 significantly reduced tumor burden in both mouse and rat models of RB.
Other notes	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
Phase I experiment:[2]
Target	Patients with solid tumours.
Dosage form	Patients with advanced solid tumours were treated with entinostat orally once weekly and with CRA orally twice daily for 3 weeks in every 4 weeks. The starting dose for entinostat was 4 mg/m2 with a fixed dose of CRA at 1 mg/kg per day. Entinostat dose was escalated by 1 mg/m2 increments.
Applications	A total of 19 patients were enrolled. The maximum tolerated dose (MTD) was exceeded at the entinostat 5 mg/m2 dose level (G3 hyponatremia, neutropenia, and anaemia). Fatigue (G1 or G2) was a common side effect. Entinostat exhibited substantial variability in clearance (147%) and exposure. The combination of entinostat with CRA was reasonably well tolerated. The recommended phase II doses are entinostat 4 mg/m2 once weekly and CRA 1 mg/kg per day. Although no tumour responses were seen, further evaluation of this combination is warranted.
References: 1. Dalgard CL, Van Quill KR, O'Brien JM. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res. 2008 May 15;14(10):3113-23. 2. Pili R1, Salumbides B, Zhao M et al. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer. 2012 Jan 3;106(1):77-84.

Biological Activity

Description	Entinostat (MS-275) is a strong inhibitor of HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, compared with HDACs 4, 6, 8, and 10.
Targets	HDAC1	HDAC3
IC50	0.51 μM	1.7 μM